Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
about
Trial watch - inhibiting PARP enzymes for anticancer therapyNew and emerging factors in tumorigenesis: an overviewAdjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyStatus of adjuvant endocrine therapy for breast cancer.Long-term risk of medical conditions associated with breast cancer treatmentExperimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitorsAdjuvant Endocrine Therapy in Early Postmenopausal Breast CancerAdverse effects of azacitidine: onset, duration, and treatment.Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer.Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectivesIndications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.Adjuvant Systemic Therapy of Breast Cancer.Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.A pilot study of website information regarding aromatase inhibitors: dietary supplement interactionsApproval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approvalRANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer PatientsLonger-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.Ethics of ongoing cancer care for patients making risky decisionsAbrogating endocrine resistance by targeting ERα and PI3K in breast cancer.Aromatase inhibitor treatment for breast cancer: short-term effect on bone healthAdjuvant hormonal therapy in premenopausal women with breast cancer.Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyPrognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG OncologFactors that predict recurrence later than 5 years after initial treatment in operable breast cancer.Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.Tamoxifen: the drug that came in from the cold.Surgical oophorectomy for breast cancer: back to the future.Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a reviewAromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update.Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
P2860
Q26745673-B3088725-67BD-4042-B674-0D96BD3AC2E3Q26801253-ACA64C2A-C6AC-4936-8B8E-6818B7437442Q27002430-4096692D-F4AD-405B-8818-D2CB58EDE7C1Q27011658-484E10C2-031F-4D33-BD54-2ADAF77651FEQ33739138-A90CD8AC-403B-4B4A-9D48-1C8555141C91Q33895877-2578727B-445E-44CE-BCEF-185F840ED603Q34082909-3A26E5A1-ED65-49F7-A555-6DC95C592930Q34096283-EE4FB873-9B4D-49A4-AC9C-4EF5FF84D22EQ34193934-B81BBF73-B902-4E16-8D28-AA0B6498D5FAQ34233815-79B03EC2-29D3-4533-BD3D-7D14A41995EBQ34303205-4CBC677C-7183-4144-9C7A-3B1D1ED28F7CQ34403564-77F921E5-6293-4C36-8E0F-1542DF31407FQ34655579-2F81237A-588F-4FE7-B7F4-E88FD45DF107Q34774649-6E35346A-2F61-4858-81FE-93DB2F468422Q34873249-98277EDA-BE8B-4386-B614-57C52B088FC9Q35095595-BA227C5C-8E51-4C4E-85EF-865F4F0186C5Q35106041-F68F0681-B41A-40AD-8575-99E74E736500Q35565585-C9758806-D62C-426D-B7B0-ED50EAC5C0D1Q35642388-B9359498-004A-4071-8EA1-666D913C8234Q35720004-3E95BEC1-B09A-45C6-A668-BE9D4B9FEFB0Q35808358-5F4FC7E5-B6ED-4AE3-A640-DE84B7A4C87BQ35847450-95E24A0C-671A-4D4B-93C2-901F3AA7FC75Q35925132-1A61CD9D-A902-45DA-9B14-62150A52BBE2Q36070063-7467E1D6-0E19-426D-BDBB-577EEF8F6FF0Q36226336-0CFD5EA4-381B-443E-B4D3-58E38B9D5382Q36321147-04C206ED-424F-42B1-BCA6-EC5DF5A1F3B7Q36452858-F85B6D6C-69F1-45A8-943A-E0429115446BQ36457989-2B6ED9DD-CFC4-49F3-A72D-AAD458CCDB91Q37103057-4819CFA2-7D08-4597-A5A4-818592B5E53DQ37169337-69AB93AD-3015-4791-9FE2-45AA351AC09EQ37199625-E6FE629B-48C2-4A04-A760-39796F5F8FEEQ37263046-6347E282-D009-4147-9257-89961C5FFB2AQ37292419-4069A5AE-F64C-4615-9E3F-38344194B2BCQ37316233-28476127-1FFC-4C17-A33C-C58F1449CA52Q37345339-82964BDF-A573-44E6-995E-B6E767DD5F50Q37351996-16406A47-38EE-41FB-B0CF-BB91BF7553AFQ37354647-ABC12853-CBBF-4027-BADE-8B3C5800D2CFQ37355574-D6598CA7-1AC8-45B2-9EEE-6E25ABA57743Q37431101-42A0E63A-5355-4D85-85DB-78C28B6F0EDBQ37463330-2FCAFB45-1FB5-4B9C-B347-CC4ED16AD178
P2860
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Late extended adjuvant treatme ...... complete 5 years of tamoxifen.
@en
Late extended adjuvant treatme ...... complete 5 years of tamoxifen.
@nl
type
label
Late extended adjuvant treatme ...... complete 5 years of tamoxifen.
@en
Late extended adjuvant treatme ...... complete 5 years of tamoxifen.
@nl
prefLabel
Late extended adjuvant treatme ...... complete 5 years of tamoxifen.
@en
Late extended adjuvant treatme ...... complete 5 years of tamoxifen.
@nl
P2093
P356
P1476
Late extended adjuvant treatme ...... complete 5 years of tamoxifen.
@en
P2093
David A Cameron
Dongsheng Tu
Edith A Perez
Hyman B Muss
James N Ingle
Jeffrey S Abrams
Joseph L Pater
Kathleen I Pritchard
Lois E Shepherd
Martine J Piccart
P304
P356
10.1200/JCO.2007.11.6798
P407
P50
P577
2008-03-10T00:00:00Z